Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.59 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CCR4 | P51679 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695847 | 0.85 | CCR4 (0.47) | APPACP1TLR7CCR4KMT2A | |
| SCHEMBL4093298 | 0.84 | APP (0.65) | APPACP1TLR7BCHEACHE | |
| SCHEMBL4602578 | 0.80 | ACHE (0.44) | APPACP1TLR7BCHEACHE | |
| SCHEMBL4602573 | 0.80 | ACHE (0.44) | APPACP1TLR7BCHEACHE | |
| SCHEMBL4602300 | 0.79 | TACR3 (0.47) | APPACHEKMT2AMAPTMEN1 | |
| SCHEMBL4602296 | 0.79 | TACR3 (0.47) | APPACHEKMT2AMAPTMEN1 | |
| SCHEMBL9260020 | 0.79 | MAPT (0.53) | APPBCHEACHEKMT2AMAPT | |
| SCHEMBL4601094 | 0.78 | CXCR2 (0.46) | APPACP1BCHEACHEKMT2A | |
| SCHEMBL4601095 | 0.78 | CXCR2 (0.46) | APPACP1BCHEACHEKMT2A | |
| SCHEMBL3970144 | 0.78 | NPY5R (0.60) | KMT2AMAPTMEN1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | APP 1979/4885ACP1 3504/4885TLR7 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.